The HOPE study Double-blind, randomized, placebo-controlled trial Over 9500 patients at high risk of cardiovascular disease 4.5-year treatment period Compared the risk of cardiovascular events with the ACE inhibitor, ramipril (10 mg/day), vs placebo, both given as add-on to existing antihypertensive therapy
{}